Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Myomar Molecular has developed a first-in-class, non-invasive urine test that detects molecular biomarkers linked to muscle health. The technology enables early detection of muscle atrophy, provides personalized scores and actionable recommendations, predicts fall risk in seniors, and supports clinical decision-making. Clinical validation includes successful beta testing in clinics; the company is now scaling up following regulatory approval from Health Canada
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Myomar Molecular.